Self-administered therapies in paroxysmal nocturnal hemoglobinuria: balancing quality of life with clinically relevant risks

INTRODUCTION: Complement inhibitors have transformed outcomes in paroxysmal nocturnal hemoglobinuria (PNH), with intravenous (IV) C5 inhibitors resulting in sustained hemolysis control, reduced thrombotic risk, and improved survival. Ongoing IV infusions, however, can be burdensome for some patients, and terminal complement blockade can result in clinically significant extravascular hemolysis (EVH) in a subset of patients. Four new self-administered agents, pegcetacoplan, iptacopan, crovalimab, and danicopan, have expanded the therapeutic landscape in PNH. AREAS COVERED: This review draws on pivotal trial data, patient-reported outcome analyses, and real-world evidence to examine the current clinical role of each agent. We searched PubMed and Google Scholar with no date range limitations, supplemented by hematology conference abstracts and regulatory documents. We weigh patient-centered benefits against clinically relevant risks, including adherence, infection risk, breakthrough hemolysis, and limited pregnancy data. We offer a practical framework for approaching self-administered therapies in PNH. EXPERT OPINION: Self-administered therapies expand options for individualized PNH care, but greater autonomy shifts responsibility for adherence and complication recognition onto patients, underscoring the continued need for structured education, patient support programs, and specialist oversight. Longer-term real-world data, particularly on adherence, breakthrough hemolysis, and pregnancy, are needed to guide patient selection and further support use of these agents.

Authors

Institutions

Publication Details

Journal
Expert Review of Hematology
Published
2026-11-18
DOI
https://doi.org/10.1080/17474086.2026.2767361
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Self-administered therapies in paroxysmal nocturnal hemoglobinuria: balancing quality of life with clinically relevant risks

Monika Oliver, Marc Bienz, Benjamin Hull Chin-Yee, Signy Chow et al.
4 links
Expert Review of Hematology
Complement system in diseases
article

Self-administered therapies in paroxysmal nocturnal hemoglobinuria: balancing quality of life with clinically relevant risks

Monika Oliver, Marc Bienz, Benjamin Hull Chin-Yee, Signy Chow, Christopher Jordan Patriquin
article en

Abstract

INTRODUCTION: Complement inhibitors have transformed outcomes in paroxysmal nocturnal hemoglobinuria (PNH), with intravenous (IV) C5 inhibitors resulting in sustained hemolysis control, reduced thrombotic risk, and improved survival. Ongoing IV infusions, however, can be burdensome for some patients, and terminal complement blockade can result in clinically significant extravascular hemolysis (EVH) in a subset of patients. Four new self-administered agents, pegcetacoplan, iptacopan, crovalimab, and danicopan, have expanded the therapeutic landscape in PNH. AREAS COVERED: This review draws on pivotal trial data, patient-reported outcome analyses, and real-world evidence to examine the current clinical role of each agent. We searched PubMed and Google Scholar with no date range limitations, supplemented by hematology conference abstracts and regulatory documents. We weigh patient-centered benefits against clinically relevant risks, including adherence, infection risk, breakthrough hemolysis, and limited pregnancy data. We offer a practical framework for approaching self-administered therapies in PNH. EXPERT OPINION: Self-administered therapies expand options for individualized PNH care, but greater autonomy shifts responsibility for adherence and complication recognition onto patients, underscoring the continued need for structured education, patient support programs, and specialist oversight. Longer-term real-world data, particularly on adherence, breakthrough hemolysis, and pregnancy, are needed to guide patient selection and further support use of these agents.

Expert Review of Hematology
Western University (CA), Sunnybrook Health Science Centre (CA), University Health Network (CA), University of Alberta (CA), University of Toronto (CA), Alberta Hospital Edmonton (CA), London Health Sciences Centre (CA), Jewish General Hospital (CA), University of Alberta Hospital (CA), McGill University (CA)
Good health and well-being
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon